Abstract | AIM: This analysis investigates incidence and time course of rash in the EURTAC study. MATERIALS & METHODS: RESULTS: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. CONCLUSION: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
|
Authors | Filippo de Marinis, Alain Vergnenegre, Antonio Passaro, Catherine Dubos-Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Perez-Moreno, Rafael Rosell |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 11
Issue 3
Pg. 421-9
( 2015)
ISSN: 1744-8301 [Electronic] England |
PMID | 25675123
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Protein Kinase Inhibitors
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(complications, drug therapy, genetics, mortality)
- ErbB Receptors
(genetics)
- Erlotinib Hydrochloride
- Exanthema
(drug therapy, epidemiology, etiology, prevention & control)
- Humans
- Incidence
- Kaplan-Meier Estimate
- Lung Neoplasms
(complications, drug therapy, genetics, mortality)
- Mutation
- Protein Kinase Inhibitors
(administration & dosage, adverse effects)
- Quinazolines
(administration & dosage, adverse effects)
- Time Factors
- Treatment Outcome
|